Aeris Therapeutics is engaged in the development and commercialization of novel therapies for patients with emphysema and other lung diseases.

Aeris Therapeutics' lead product is the AeriSeal System. It is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema.

Emphysema affects as many as 60 million patients worldwide. 

In Europe
The AeriSeal System has received CE Mark approval.

In United States
Caution: The AeriSeal System is an investigational device limited by federal law to investigational use.